Metformin Hydrochloride; Saxagliptin Hydrochloride Patent Expiration
Metformin Hydrochloride; Saxagliptin Hydrochloride is Used for improving glycemic control in adults with type 2 diabetes mellitus. It was first introduced by Astrazeneca Ab
Metformin Hydrochloride; Saxagliptin Hydrochloride Patents
Given below is the list of patents protecting Metformin Hydrochloride; Saxagliptin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kombiglyze Xr | US8628799 | Coated tablet formulation and method |
Jul 13, 2025
(Expired) | Astrazeneca Ab |
| Kombiglyze Xr | US9339472 | Coated tablet formulation and method |
Jul 13, 2025
(Expired) | Astrazeneca Ab |
| Kombiglyze Xr | USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul 31, 2023
(Expired) | Astrazeneca Ab |
| Kombiglyze Xr | US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb 16, 2021
(Expired) | Astrazeneca Ab |
Metformin Hydrochloride; Saxagliptin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List